Technical Data Sheet

InVivoSIM anti-human IL-17RA (Brodalumab biosimilar)

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: **Lot Specific***
Volume: **Lot Specific***
Concentration: **Lot Specific* (generally 4 to 11 mg/ml) ***
Total Protein: **Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	**SIM0121**
Clone:	**Brodalumab**
Isotype:	Human IgG2, κ
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Immunogen:	IL-17RA
Reported Applications:	*in vivo* functional assays *in vitro* functional assays ELISA Flow cytometry
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	≤0.5EU/mg (≤0.0005EU/µg) Determined by LAL assay
Purity:	≥95% Determined by SDS-PAGE
Sterility:	0.2 µm filtration
Production:	Purified from cell culture supernatant in an animal-free facility
Purification:	Protein A
Aggregation:	<5% Determined by SEC
RRID:	

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

This biosimilar antibody uses the same variable regions as the therapeutic antibody Brodalumab, making it ideal for research use. Brodalumab is a human IgG2 monoclonal antibody that specifically targets interleukin-17 receptor A (IL-17RA), a key receptor that mediates signaling of multiple IL-17 family cytokines, including IL-17A, IL-17F, and IL-17A/F heterodimers. IL-17RA is broadly expressed on keratinocytes, epithelial cells, fibroblasts, and various immune cells, where it drives pro-inflammatory responses through activation of downstream pathways such as NF-κB. By binding to IL-17RA, Brodalumab blocks IL-17–mediated signaling, reducing the production of pro-inflammatory cytokines, chemokines, and antimicrobial peptides. This pathway plays a central role in chronic inflammatory diseases, particularly psoriasis, where IL-17 signaling contributes to keratinocyte hyperproliferation and sustained inflammation. This Brodalumab biosimilar is well suited

for studying IL-17 signaling, epithelial inflammation, and immune-mediated disease mechanisms.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**
It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/faqs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/invivosim-anti-human-il-17ra-brodalumab-biosimilar-sim0121?utm_source=cr9k1b#tab_references or scan the QR code below.

Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com